TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12577455
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition in dose of 26.5 kcal/kg and 1 g of amino acid/kg given to patients who did not reach adequate oral intake for 5 days
Study: 10199111
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) titrated to a dose of 0.7 mg/kg
Study: 1830259
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin delivery (15 units of insulin in 1% sodium glycocholate)
Study: 6858980
Drug: Suppository group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository group
Study: 26965165
Drug: 8-week, group-based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week, group-based, behaviour-change programme with weekly 90-min sessions about healthy eating and physical activity
Study: 24633809
Drug: MNRP1685A (7.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNRP1685A (7.5, 15, 24, and 36 mg/kg) with bevacizumab 15 mg/kg every 3 weeks (Arm A)
Study: 24633809
Drug: MNRP1685A (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNRP1685A (12 and 16 mg/kg) with bevacizumab 10 mg/kg every 2 weeks and paclitaxel 90 mg/m(2) weekly (Arm B)
Study: 24633809
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MNRP1685A with bevacizumab
Study: 24399119
Drug: IDIProst® Gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDIProst® Gold (one capsule q24 h) for 3 months
Study: 24399119
Drug: Serenoa repens
Normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serenoa repens 320 mg (one capsule q24h) for 3 months
Study: 17953792
Drug: Lornoxicam (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (24 mg day(-1))
Study: 17953792
Drug: Dipyrone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (5 g day(-1))
Study: 16904312
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy with vincristine and actinomycin D for 6 weeks
Study: 10819345
Drug: Nonavalent protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonavalent protein conjugate pneumococcal vaccine (PnCV)
Study: 1394200
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant interleukin 2
Study: 7362696
Drug: Clofibate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibate (2 g/day)
Study: 30882846
Drug: Pioglitazone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone therapy
Study: 29720113
Drug: Guideline-driven antiemetic
Normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guideline-driven antiemetic therapy
Study: 29720113
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent antiemetic therapy with haloperidol
Study: 26746868
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg) administered via four monthly intravitreal injections and then as needed per protocol
Study: 25155371
Drug: Bevacizumab (Avastin);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (Avastin); administered every 4 weeks, pro re nata.
Study: 25155371
Drug: Dexamethasone implant
Normalized name: dexamethasone Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone implant (Ozurdex); administered every 16 weeks, pro re nata.
Study: 25155371
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Bevacizumab and Dexamethasone implant)
Study: 22368041
Drug: Proximal esophageal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proximal esophageal pH capsule
Study: 20415839
Drug: Hyperbaric Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric Oxygen Therapy (HBO(2)T) administered in a course of 20 treatments at pressures between 1.75ATA and 2.5ATA daily for 60-120 min over 4 weeks
Study: 18541979
Drug: donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil (5 mg, n=11 or 10 mg, n=1)
Study: 16358411
Drug: Liuwei Dihuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liuwei Dihuang pill (LWDH)
Study: 16358411
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Conventional treatment with prednisone and CTX)
Study: 12869000
Drug: Custom-made screw
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custom-made screw implants with plaque control terminated at one implant and continued at the other implant after one month of abutment connection.
Study: 12869000
Drug: Custom-made screw
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custom-made screw implants with varying periods of plaque accumulation (7, 21, or 90 days).
Study: 7970453
Drug: Low-dose RU
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose RU 486 (5 mg alternate days for four doses, beginning 3 days after the urinary LH surge)
Study: 11317155
Drug: Clonidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (300 mg)
Study: 10897972
Drug: Finasteride 1
Normalized name: finasteride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 1 mg daily
Study: 7640038
Drug: Intensive weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intensive weekly regimen of cisplatin (70-85 mg/m2)
Study: 7640038
Drug: 3-weekly combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-weekly combination chemotherapy with cisplatin (75 mg/m2)
Study: 7640038
Drug: 3-weekly regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-weekly regimen with cisplatin (20 mg/m2 for 5 days)
Study: 28531469
Drug: Ezetimibe therapy
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe therapy
Study: 19055335
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (once a week for 10 weeks, in addition to conservative treatment with medication)
Study: 19055335
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with medication only (control group)
Study: 16899485
Drug: Subcutaneous treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous treprostinil monotherapy
Study: 16899485
Drug: Subcutaneous treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous treprostinil in idiopathic pulmonary arterial hypertension (IPAH) patients
Study: 10663618
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy with idarubicin, ara-C, etoposide
Study: 10663618
Drug: IL-2 treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IL-2 treatment arms (high-dose vs low-dose)
Study: 2135254
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 400 mg ibuprofen
Study: 2135254
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 600 mg ibuprofen with 2 x 6 mg dexamethasone
Study: 30169605
Drug: HINE E-GEL®
Approvals — FDA: no, EMA: no, PMDA: no
Description: HINE E-GEL®
Study: 28052915
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of CDCs
Study: 28052915
Drug: Late CDC
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late CDC infusion in controls
Study: 28052915
Drug: Overall CDC
Normalized name: CDC-801
DrugBank: CDC-801 (DB15640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall CDC infusion
Study: 26107818
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) plus standard MMT
Study: 16368038
Drug: Once-monthly ibandronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-monthly ibandronate
Study: 11952431
Drug: Remifentanil (R)
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil (R) administered in incremental dosages (0.1-0.25-0.5 microg/kg/min)
Study: 11952431
Drug: Fentanyl (F)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl (F) 1.5 microg/kg and midazolam (M) titrated between 1 and 10 mg
Study: 9467551
Drug: Threshold dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold dose plus 1/2 ampoule of FSH
Study: 9467551
Drug: 1 ampoule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ampoule above the threshold dose of FSH
Study: 9467551
Drug: Threshold dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold dose of FSH
Study: 8699040
Drug: Conventional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous infusion of oxytocin
Study: 2550167
Drug: Nadolol (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (240 mg per day, increased weekly for 4 weeks)
Study: 2550167
Drug: Propranolol (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (240 mg per day, increased weekly for 4 weeks)
Study: 6457170
Drug: ABPC (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABPC (2 g)
Study: 30935548
Drug: Purslane cream
Normalized name: Purslane
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purslane cream (2% w/w)
Study: 17767120
Drug: Lanolin ointment
Normalized name: Lanolin
DrugBank: Lanolin (DB11112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanolin ointment
Study: 28734858
Drug: 5-grass pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-grass pollen tablet
Study: 26098833
Drug: Jinlida (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinlida (9 g) TID for 12 weeks
Study: 7752258
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium carbonate (CaCO3) supplements (1.5 g) three times a day for 12 weeks
Study: 1703920
Drug: Nitroglycerin tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin tape (5 mg) and ibopamine (100 mg)
Study: 1703920
Drug: Nitroglycerin tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin tape (5 mg) and nifedipine (10 mg)
Study: 23419134
Drug: Cediranib 20
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 20 mg orally daily
Study: 23419134
Drug: Cediranib 20
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 20 mg orally daily + Prednisone 10 mg daily
Study: 17942470
Drug: Sertraline for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline for 4 months
Study: 15477504
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) treatment (2-g/kg loading dose, boosters of 0.4 g/kg every 6 weeks for 1 year)
Study: 11825312
Drug: Inhibitors of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitors of platelet aggregation (including nitric oxide from L-arginine or glyceryl trinitrate) and anticoagulants (low molecular weight heparin, defibrotide)
Study: 11825312
Drug: Intravenous infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusions of prostaglandins (PGs) PGE1 and PGI2
Study: 11825312
Drug: Propionyl-L-carnitine and
Normalized name: glycine propionyl-L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine and basic fibroblast growth factor (bFGF)
Study: 8172381
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (GTN) applied every eight hours until disappearance of inflammation signs.
Study: 8172381
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied every eight hours until disappearance of inflammation signs.
Study: 3278754
Drug: 13-cis retinoic
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13-cis retinoic acid (13-CRA, 100 mg/m2)
Study: 31925721
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 mg daily)
Study: 30128934
Drug: Leukocyte-poor platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte-poor platelet-rich plasma (LP-PRP) injection
Study: 28536030
Drug: Combination Hib-TT
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Hib-TT vaccine
Study: 7118100
Drug: Part-time supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part-time supportive treatment program
Study: 16342005
Drug: Lithium administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium administration
Study: 30399035
Drug: Lay worker
Normalized name: Apis cerana worker secretion preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lay worker administered combination intervention (individualized health education, retention/adherence support, appointment reminders, missed visit tracking)
Study: 30463598
Drug: usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: usual care (medical treatment)
Study: 20232572
Drug: Fexofenadine 120
Normalized name: fexofenadine hydrochloride 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 120 mg daily
Study: 17047171
Drug: hGH (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGH (0.1 mg/kg/d for 3 weeks, then 0.1 mg/kg 3 days a week for 8 weeks)
Study: 17047171
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous saline)
Study: 14609147
Drug: AAS administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AAS administration with resistance training
Study: 3998786
Drug: Blood transfusions
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood transfusions during definitive surgical therapy
Study: 3998786
Drug: No blood
Normalized name: VivaGuard Ino Blood Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: No blood transfusions during definitive surgical therapy
Study: 3998786
Drug: Blood transfusions
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood transfusions in patients receiving chemotherapy
Study: 3998786
Drug: Blood transfusions
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood transfusions in patients with large tumors (greater than 150 mL)
Study: 26968881
Drug: Metronidazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (400 mg) plus penicillin (1,000,000 IU) for 10 days and 7 days respectively
Study: 25362813
Drug: Imatynib-Biofarm 100
Normalized name: imatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatynib-Biofarm 100 mg film-coated tablet (test)
Study: 25362813
Drug: Imatynib-Biofarm 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatynib-Biofarm 400 mg film-coated tablet (test)
Study: 12021830
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g oral glucose tablets
Study: 10423646
Drug: 4 tablets
Normalized name: Ribasphere RibaPak 800, 4 Unit Dose Packs, 14 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets of potassium-magnesium citrate per day
Study: 10423646
Drug: 7 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 tablets of potassium-magnesium citrate per day
Study: 10423646
Drug: 10 tablets
Normalized name: ALLANTOIN 0.11 in 600 mg VAGINAL TABLET [Jilgyungyi (10 Tablets)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 tablets of potassium-magnesium citrate per day
Study: 6271386
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide alone
Study: 30949233
Drug: RG method
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG method integrated in Flexible Assertive Community Treatment (FACT)
Study: 24004959
Drug: Tocopheryl acetate
Normalized name: Tocopheryl acetate
DrugBank: alpha-Tocopherol acetate (DB14003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tocopheryl acetate 20% spray
Study: 14646190
Drug: TACC-supplemented tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACC-supplemented tea (1.1 mg thiamin, 1240 mg arginine, 52 mg caffeine, 540 mg citric acid); n=16
Study: 8096549
Drug: Denopamine 40
Normalized name: dopamine hydrochloride 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denopamine 40 mg/day
Study: 3517554
Drug: Hydrocortisone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (80 mg by mouth)
Study: 29532075
Drug: 1.3 g/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 g/kg/d of protein plus testosterone
Study: 29532075
Drug: 1.3 g/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 g/kg/d of protein plus placebo
Study: 29532075
Drug: 0.8 g/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg/d of protein plus testosterone
Study: 29532075
Drug: 0.8 g/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg/d of protein plus placebo
Study: 21855173
Drug: E2 (estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 (estradiol patch)
Study: 21855173
Drug: E2+CORT (estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2+CORT (estradiol patch/hydrocortisone)
Study: 20973322
Drug: 0.0125% capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0125% capsaicin gel applied three times daily for 4 weeks
Study: 20973322
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied three times daily for 4 weeks
Study: 18419724
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg of 10 mg/ml isobaric 2-chloroprocaine
Study: 18419724
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of 10 mg/ml isobaric 2-chloroprocaine
Study: 18419724
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of 10 mg/ml isobaric 2-chloroprocaine
Study: 11794431
Drug: Tibolone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 1.25 mg once/day for 7 days
Study: 11794431
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg once/day for 7 days
Study: 11794431
Drug: Tibolone 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 5.0 mg once/day for 7 days
Study: 9724142
Drug: Long-term omeprazole
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term omeprazole treatment
Study: 8040761
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) at a dosage of 0.5 U/kg per week (group 1: 4 boys, 3 girls)
Study: 8040761
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) at a dosage of 1.0 U/kg per week (group 2: 6 boys, 2 girls)
Study: 20837371
Drug: Atorvastatin up-titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin up-titration (40 mg to 80 mg or 20 mg to 40 mg)
Study: 16181608
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored behavioral medicine treatment
Study: 11468787
Drug: No previous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No previous treatment to eradicate the infection
Study: 11468787
Drug: Previous eradication
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous eradication therapies
Study: 9196518
Drug: BAYx 1005
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAYx 1005 (500 mg twice daily)
Study: 1436339
Drug: r‐HuEPO administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO administered intravenously
Study: 1436339
Drug: r‐HuEPO administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO administered subcutaneously
Study: 1436339
Drug: r‐HuEPO (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO (both intravenous and subcutaneous)
Study: 23945376
Drug: Artemisinin-combination therapy
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin-combination therapy (ACT)
Study: 21346060
Drug: GIN therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIN therapy (n = 49)
Study: 19656386
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care support programme in primary care
Study: 12666948
Drug: Braun Oral-B
Normalized name: bran Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral-B 3D Plaque Remover (three-dimensional oscillating/rotating/pulsating action)
Study: 3309021
Drug: Maintenance cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintenance cimetidine (400 mg at bedtime)
Study: 22578110
Drug: NSAID (rofecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID (rofecoxib 50 mg)
Study: 20947859
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) at doses of 30-180 μg/kg over 3 days
Study: 14712889
Drug: Topical brimonidine
Normalized name: brimonidine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical brimonidine 0.2% b.d. (n = 90)
Study: 14712889
Drug: Topical dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dorzolamide 2% b.d. (n=91)
Study: 14712889
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost 0.005% o.d. (n = 91)